Am J Transplant, Volume 18, Suppl 3 Archives - Page 189 of 211 - ATC Abstracts

2018 American Transplant Congress
Assessment of Immune Cell Profiles in HLA-Sensitized (HS) & Non-HS Patients (Pts) with End Stage Renal Disease (ESRD)
S. Ge,¹ M. Chu,¹ E. Ortiz,¹ A. Vo,² D. Lovato,¹ S. Jordan,² M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Chronic inflammation is often seen in pts w/ ESRD. HLA-sensitization may create or be driven by the cytokines responsible for chronic inflammation. Here we…
2018 American Transplant Congress
Sensing T Cell Killing Activity with Granzyme B Activity Probes
Q. Mac,¹ D. Mathews,² J. Kahla,¹ C. Stoffers,¹ O. Delmas,¹ B. Holt,¹ A. Adams,² G. Kwong.¹
¹Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA; ²Department of Surgery, Emory University School of Medicine, Atlanta, GA.
Purpose: We developed activity-based probes that sense Granzyme B (GzmB) activity during alloreactive T cell killing of donor cellsMethods: FITC-labelled GzmB substrate (IEFDSG) was synthesized…
2018 American Transplant Congress
Rictor mTORC2 Signaling Protects Ischemic Liver Injury by Targeting Both Liver Parenchymal and Non-Parenchymal Cells
H. Zhou,¹ Z. Rao,¹ R. Liu,¹ S. Zhou,¹ J. Rao,¹ J. Gu,¹ H. Lu,¹ Y. Xia,¹ X. Wang,¹ Y. Zhai,² L. Lu.¹
¹First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ²David Geffen School of Medicine at University of California-Los Angeles, Los Angeles.
Background and Aims:Mammalian target of rapamycin (mTOR) signaling controls many essential cellular functions. However, the role and its underlying mechanism of Rictor/mTOR complex 2 (mTORC2)…
2018 American Transplant Congress
Ischemic Preconditioning Ameliorates Renal Ischemia-Reperfusion Injury in Mice via Heme Oxygenase-1-Mediated Autophagy
J. Hwang,² H. Choi,¹ M. Kim,² K. Jun,² K. Kown,² S. Park,² J. Kim,² I. Moon.²
¹Clinical Research, Daejeon St. Mary's Hospital, Daejeon, Korea; ²Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Recent data from animal experiments and clinical trials indicate that ischemic preconditioning (IPC) confers protection from renal ischemia-reperfusion (I/R) injury. Nevertheless, the underlying mechanisms for…
2018 American Transplant Congress
Protocolar Biopsies in Patients with Subclinical De Novo DSA in Kidney Transplantation
D. Bertrand,¹ M. Jaureguy,² C. Garrouste,³ J. Sayegh,⁴ N. Bouvier,⁵ S. Caillard,⁶ L. Lanfranco,⁷ A. Galinier,⁸ A. François,⁹ F. Hau,¹⁰ I. Etienne,¹ P. Gatault.¹¹
¹Nephrology Kidney Transplantation Dialysis, CHU Rouen, Rouen, France; ²Nephrology Kidney Transplantation, CHU Amiens, Amiens, France; ³Nephrology Kidney Transplantation, CHU Clermont Ferrand, Clermont Ferrand, France; ⁴Nephrology Kidney Transplantation, CHU Angers, Angers, France; ⁵Nephrology Kidney Transplantation, CHU Caen, Caen, France; ⁶Nephrology Kidney Transplantation, CHU Strasbourg, Strasbourg, France; ⁷Nephrology Kidney Transplantation, CHU Brest, Brest, France; ⁸Nephrology Kidney Transplantation, CHU Poitiers, Poitiers, France; ⁹Pathology, CHU Rouen, Rouen, France; ¹⁰EFS Normandie, EFS Normandie, Rouen, France; ¹¹Nephrology Kidney Transplantation, CHU Tours, Tours, France.
De novo donor-specific antibody (DSA) is associated with antibody-mediated rejection (ABMR) and allograft loss. The aim of our study was to examine the histology associated…
2018 American Transplant Congress
Subclass Distribution of DSA Analyzed by Mass Spectrometry Predicts the Risk of Humoral Rejection
V. Pernin,^1,2 N. Bec,³ C. Larroque,³ C. Duperray,² G. Mourad,¹ M. Lequintrec.^1,2
¹Department of Nephrology, Dialysis and Kidney Transplantation, CHU Lapeyronie, Montpellier, France; ²INSERM U1183 Institute for Regenerative Medicine & Biotherapy (IRMB), Montpellier, France; ³Institut de Recherche en Cancérologie de Montpellier (IRCM)- CRLC Val d'Aurelle - Paul Lamarque - INSERM U896, Montpellier, France.
Background :DSA occurrence after kidney transplant is a main risk factor for humoral rejection and graft loss, however graft outcomes after DSA detection is very…
2018 American Transplant Congress
Comparison of C1Q Binding and Flow Cytometric Crossmatch Results Provides an Accurate Evaluation of Hypersensitive Kidney Transplant Patients
E. Eksioğlu-Demiralp,¹ A. Türkmen,² B. Yelken,² S. Görçin,² O. Elbasi,¹ F. Yalçin,³ B. Koçak,² C. Karatas,⁴ M. Tuncer,⁴ M. Altinel.³
¹Tissue Typing and Immunology Laboratory, Memorial Health Group, Istanbul, Turkey; ²Sisli Hospital Transplantation Unit, Memorial Health Group, Istanbul, Turkey; ³Hizmet Hospital Transplantation Unit, Memorial Health Group, Istanbul, Turkey; ⁴Atasehir Hospital Transplantation Unit, Memorial Health Group, Istanbul, Turkey.
Measurement of C1q binding to Donor specific antibodies (DSA) gives transplantation chance to hypersensitive patients having non-binding high amount of anti-HLA antibodies. In our series…
2018 American Transplant Congress
Risk Factors for Graft Failure in Kidney Transplant Recipients with Polycystic Kidney Disease
G. Bhutani, B. Astor, A. Djamali.
University of Wisconsin, Madison.
Background: Polycystic kidney disease (PKD) is the underlying renal disease in 15% of kidney transplant recipients (KTRs) in the US. Post-transplant outcomes and contributing factors…
2018 American Transplant Congress
Anti-IdeS Antibodies in IVIg and Its Effect on IdeS Activity
A. Runström,¹ S. Järnum,¹ S. Jordan,² L. Winstedt,¹ C. Kjellman.¹
¹Hansa Medical AB, Lund, Sweden; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles.
ObjectiveEvaluate how and why intravenous gamma globulin (IVIg) affects IdeS-cleavage of IgG.IntroductionIgG degrading enzyme of Streptococcus pyogenes (IdeS) cleaves human IgG in two steps, first…
2018 American Transplant Congress
Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients
I. Helanterä,¹ F. Ortiz,² R. Loginov,³ L. Mannonen,³ M. Lempinen,¹ I. Lautenschlager.³
¹Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland; ²Nephrology, Helsinki University Hospital, Helsinki, Finland; ³Virology, Helsinki University Hospital, Helsinki, Finland.
A. Prophylaxis has mostly replaced preemptive therapy in CMV seronegative recipients of kidneys from seropositive donors (D+/R-). Primary infections occur commonly even after six months…